Educational content only. Not medical advice. The content creators are not doctors or medical professionals. Consult your healthcare provider before taking any action.
Quick answer
Semaglutide costs about $1,000–$1,350 per month at U.S. list price in 2026 (Ozempic ~$1,027; Wegovy ~$1,349). Most people pay far less: Novo Nordisk self-pay runs roughly $199–$499/month, and commercially insured patients with a savings card can pay as little as $25/month.
Semaglutide costs roughly $1,000–$1,350 per month at U.S. list price in 2026 (Ozempic ~$1,027; Wegovy ~$1,349). Most people pay far less: self-pay programs run about $199–$499/month, and insured patients with a savings card can pay as little as $25/month. This guide breaks down every price tier.
Semaglutide cost at a glance (2026)
| Path to access | Typical monthly cost |
|---|---|
| Wegovy list price (NovoCare) | ~$1,349.02 |
| Ozempic list price (NovoCare) | ~$1,027.51 |
| NovoCare self-pay (Wegovy/Ozempic pen) | $349–$499 |
| NovoCare self-pay intro offer (new patients, lower doses) | $199 (first 2 months) |
| Oral semaglutide self-pay (Wegovy/Rybelsus pill) | from ~$149 |
| Commercial insurance + savings card | as little as $25 |
| TrumpRx direct-to-consumer (announced) | ~$350 |
| Compounded semaglutide (telehealth, where available) | ~$150–$400 |
| Announced 2027 list price (Jan. 1, 2027) | $675 |
What is semaglutide and which products contain it?
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — a peptide-based medication that mimics a gut hormone influencing blood sugar, appetite, and gastric emptying. It is FDA-approved and sold by Novo Nordisk under three brand names: Ozempic (injectable, type 2 diabetes), Wegovy (injectable and oral, chronic weight management), and Rybelsus (oral, type 2 diabetes).
Because all three are the same active molecule at different doses and indications, "how much does semaglutide cost" has no single answer. The price depends on which brand you're prescribed, your insurance, and whether you buy through a self-pay pharmacy program. For a deeper look at the molecule itself, see our semaglutide complete guide.
This is a cost overview, not a recommendation to use any product. Consult your healthcare provider before starting any peptide or GLP-1 protocol.
How much does semaglutide cost without insurance?
At full U.S. list price, the Wegovy pen and pill each carry a list price of $1,349.02 per monthly package, and the Ozempic pen carries a list price of $1,027.51 per month (per pen), per Novo Nordisk's NovoCare pricing pages (NovoCare, 2026). The oral Ozempic/Rybelsus tablet lists at roughly $997.58 per month (NovoCare, 2026).
However, very few cash patients pay the full list price. Novo Nordisk's NovoCare Pharmacy self-pay program offers substantially lower direct prices. Standard self-pay pricing is about $349 per month for the Wegovy and Ozempic pens at common doses, with the Ozempic 2 mg dose at $499 per month and the Wegovy HD 7.2 mg pen at $399 per month (NovoCare, 2026). Oral semaglutide self-pay starts at around $149 per month (Wegovy.com, 2026).
For new patients, Novo Nordisk launched an introductory self-pay offer of $199 per month for the first two fills of lower-dose Wegovy or Ozempic, effective November 17, 2025 (Novo Nordisk press release, 2025). Promotional windows change frequently, so verify current terms directly with NovoCare before relying on a specific figure.
Consult your healthcare provider and pharmacist to confirm which price applies to your prescription.
How much does semaglutide cost with insurance?
For patients with commercial (non-government) insurance that covers semaglutide, Novo Nordisk's savings card can lower out-of-pocket cost to as little as $25 per month, subject to a maximum savings of $100 per month, per the official Wegovy pricing page (Wegovy.com, 2026). Actual cost depends on your plan's formulary tier, deductible, and prior-authorization requirements.
Coverage is uneven. Many commercial plans cover Ozempic and Rybelsus for type 2 diabetes but exclude or restrict Wegovy for weight management. Patients on Medicare or Medicaid are generally not eligible for manufacturer savings cards, which is why government-program patients often face different costs.
A major shift is underway here. Under a November 2025 federal agreement, the White House announced Medicare prices for Ozempic, Wegovy, Mounjaro, and Zepbound would be set at $245 per month with a $50 monthly co-pay for eligible beneficiaries (White House Fact Sheet, 2025). Separately reported CMS Inflation Reduction Act negotiations cite a semaglutide Medicare price near $274/month [VERIFY: $274 IRA-negotiated figure vs. $245 MFN co-pay figure are reported by different sources/programs]. Confirm your specific coverage with your plan, as these figures phase in for 2027.
How much does compounded semaglutide cost — and is it still available?
Compounded semaglutide — a non-brand version prepared by a compounding pharmacy — historically cost far less, roughly $150–$400 per month through telehealth providers (industry reporting, 2025–2026). That market has narrowed sharply.
The FDA declared the semaglutide shortage resolved on February 21, 2025 (FDA / Healio, 2025). Because large-scale compounding of an FDA-approved drug is generally only permitted during a shortage, the FDA set wind-down deadlines: enforcement discretion for 503A pharmacies ended April 22, 2025, and for 503B outsourcing facilities ended May 22, 2025 (FDA / Healio, 2025). After those dates, mass compounding of semaglutide "essentially a copy" of Ozempic or Wegovy is no longer permitted.
Limited patient-specific 503A compounding may still occur when a licensed prescriber documents a clinically significant difference for an individual patient (for example, a documented allergy to an inactive ingredient) — but this is a narrow exception, not a path to routine low-cost access, and it remains contested. The FDA has also moved to keep semaglutide off the 503B bulks list. Anyone offered "cheap compounded semaglutide" online today should verify the pharmacy's licensure and the legal basis for the prescription. Legal status varies by jurisdiction; consult a lawyer for binding advice.
Will semaglutide get cheaper in 2026 and 2027?
Yes — large announced reductions are scheduled. Novo Nordisk announced it will cut the U.S. list price of Ozempic and Wegovy to $675 per month effective January 1, 2027, roughly a 50% cut for Wegovy and about 35% for Ozempic (CNN; CNBC, 2026). Both Novo Nordisk and Eli Lilly also signed agreements to sell direct to consumers through the federal TrumpRx platform, with Ozempic and Wegovy self-pay prices reported to fall to about $350 per month (White House Fact Sheet, 2025).
These are announced figures with future effective dates; pricing programs and intro offers change often. Always confirm current pricing with NovoCare, your pharmacy, and your insurer before budgeting.
Frequently asked questions
Q: How much does semaglutide cost per month in 2026? A: It ranges from about $25 to roughly $1,350 per month depending on the path. List prices are about $1,027 (Ozempic) and $1,349 (Wegovy). Novo Nordisk's self-pay program runs about $199–$499 per month, oral semaglutide starts near $149, and commercial-insurance patients with a savings card can pay as little as $25 per month. Confirm exact pricing with your provider, pharmacy, and insurer.
Q: Why is Wegovy more expensive than Ozempic?
A: Wegovy and Ozempic both contain semaglutide, but Wegovy is dosed higher and approved for chronic weight management, while Ozempic is approved for type 2 diabetes. Wegovy's list price ($1,349/month) is higher than Ozempic's ($1,027/month). Insurance coverage also differs: weight-management coverage is more often excluded than diabetes coverage, which affects what you actually pay.
Q: Is compounded semaglutide cheaper, and is it legal in 2026? A: Compounded semaglutide was historically cheaper (about $150–$400/month), but the FDA declared the shortage resolved on February 21, 2025, and ended enforcement discretion for routine compounding (503A by April 22, 2025; 503B by May 22, 2025). Mass-market compounded copies are no longer permitted. Narrow patient-specific compounding may still occur under strict conditions. Verify any offer's legality with a licensed pharmacy and provider.
Q: Can I get semaglutide for $25 a month? A: Possibly, if you have commercial (non-government) insurance that covers it and use Novo Nordisk's savings card, which can lower cost to as little as $25/month (maximum $100/month savings). Medicare and Medicaid patients are generally not eligible for the savings card. Eligibility, formulary placement, and prior authorization all affect your final out-of-pocket cost.
Q: How much will semaglutide cost in 2027? A: Novo Nordisk announced a new list price of $675 per month for Ozempic and Wegovy effective January 1, 2027 — about half the current Wegovy price. Self-pay prices through the TrumpRx platform were reported around $350/month, and Medicare prices around $245/month with a $50 co-pay. These figures are announced for future dates; confirm before relying on them.
Q: Does insurance cover semaglutide for weight loss? A: Coverage varies widely. Many commercial plans cover Ozempic and Rybelsus for type 2 diabetes but restrict or exclude Wegovy for weight management. Some employers add weight-management coverage; others do not. Medicare historically did not cover obesity drugs, though that is changing for 2027 under federal agreements. Check your specific plan's formulary and prior-authorization rules with your insurer.
Q: Is semaglutide a peptide? A: Yes. Semaglutide is a synthetic peptide and a GLP-1 receptor agonist, structurally based on the human GLP-1 hormone. Unlike research peptides, it is FDA-approved and prescription-only. For background on how GLP-1 peptides work, see our GLP-1 peptides explained overview. Consult your healthcare provider before starting any GLP-1 or peptide protocol.
References
- NovoCare. Wegovy® (semaglutide) Cost, Coverage, & Savings Resources. Novo Nordisk. https://www.novocare.com/patient/medicines/wegovy.html
- NovoCare. Ozempic® (semaglutide) injection List Price & Insurance Coverage Explained. Novo Nordisk. https://www.novocare.com/diabetes/products/ozempic/explaining-list-price.html
- Wegovy.com. Wegovy® Cost & Coverage Information. Novo Nordisk. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
- Novo Nordisk. Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month. PR Newswire, Nov. 17, 2025. https://www.prnewswire.com/news-releases/novo-nordisk-launches-introductory-self-pay-offer-for-wegovy-and-ozempic-for-199-per-month-302617100.html
- Healio. FDA removes semaglutide from drug shortage list. Feb. 21, 2025. https://www.healio.com/news/endocrinology/20250221/fda-removes-semaglutide-from-drug-shortage-list
- The White House. Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. Nov. 2025. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/
- CNBC. Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50%. Feb. 24, 2026. https://www.cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html
Written By
Editorial team. We cite published research; we are not licensed clinicians and content is not medically reviewed.
Medical Disclaimer
The information on this website is for educational purposes only and is not medical advice. The content creators are not doctors or medical professionals. This content should not be used to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare provider before starting any new supplement, medication, or health protocol. You assume all risks associated with using this information.